BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 25213377)

  • 1. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
    Kuehn HS; Ouyang W; Lo B; Deenick EK; Niemela JE; Avery DT; Schickel JN; Tran DQ; Stoddard J; Zhang Y; Frucht DM; Dumitriu B; Scheinberg P; Folio LR; Frein CA; Price S; Koh C; Heller T; Seroogy CM; Huttenlocher A; Rao VK; Su HC; Kleiner D; Notarangelo LD; Rampertaap Y; Olivier KN; McElwee J; Hughes J; Pittaluga S; Oliveira JB; Meffre E; Fleisher TA; Holland SM; Lenardo MJ; Tangye SG; Uzel G
    Science; 2014 Sep; 345(6204):1623-1627. PubMed ID: 25213377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
    Schubert D; Bode C; Kenefeck R; Hou TZ; Wing JB; Kennedy A; Bulashevska A; Petersen BS; Schäffer AA; Grüning BA; Unger S; Frede N; Baumann U; Witte T; Schmidt RE; Dueckers G; Niehues T; Seneviratne S; Kanariou M; Speckmann C; Ehl S; Rensing-Ehl A; Warnatz K; Rakhmanov M; Thimme R; Hasselblatt P; Emmerich F; Cathomen T; Backofen R; Fisch P; Seidl M; May A; Schmitt-Graeff A; Ikemizu S; Salzer U; Franke A; Sakaguchi S; Walker LSK; Sansom DM; Grimbacher B
    Nat Med; 2014 Dec; 20(12):1410-1416. PubMed ID: 25329329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balance and imbalance in the immune system: life on the edge.
    Topalian SL; Sharpe AH
    Immunity; 2014 Nov; 41(5):682-4. PubMed ID: 25517610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterozygous
    Mahat U; Ambani NM; Rotz SJ; Radhakrishnan K
    Pediatr Hematol Oncol; 2021 Oct; 38(7):658-662. PubMed ID: 33900894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What did we learn from CTLA-4 insufficiency on the human immune system?
    Mitsuiki N; Schwab C; Grimbacher B
    Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
    Lanz AL; Riester M; Peters P; Schwerd T; Lurz E; Hajji MS; Rohlfs M; Ley-Zaporozhan J; Walz C; Kotlarz D; Klein C; Albert MH; Hauck F
    Clin Immunol; 2021 Aug; 229():108779. PubMed ID: 34116213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy.
    Ureshino H; Koarada S; Kamachi K; Yoshimura M; Yokoo M; Kubota Y; Ando T; Ichinohe T; Morio T; Kimura S
    Int J Hematol; 2020 Jun; 111(6):897-902. PubMed ID: 31993940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunology. Autoimmunity by haploinsufficiency.
    Rieux-Laucat F; Casanova JL
    Science; 2014 Sep; 345(6204):1560-1. PubMed ID: 25258064
    [No Abstract]   [Full Text] [Related]  

  • 9. A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer.
    Hayakawa S; Okada S; Tsumura M; Sakata S; Ueno Y; Imai K; Morio T; Ohara O; Chayama K; Kobayashi M
    J Clin Immunol; 2016 Jan; 36(1):28-32. PubMed ID: 26644313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
    Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
    Front Immunol; 2019; 10():998. PubMed ID: 31156616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.
    Burnett DL; Parish IA; Masle-Farquhar E; Brink R; Goodnow CC
    Immunol Cell Biol; 2017 Oct; 95(9):775-788. PubMed ID: 28611475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential Expansion of Foxp3
    Stohl W; Yu N; Wu Y
    Immunohorizons; 2022 Jul; 6(7):507-514. PubMed ID: 35878937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.
    Schwab C; Gabrysch A; Olbrich P; Patiño V; Warnatz K; Wolff D; Hoshino A; Kobayashi M; Imai K; Takagi M; Dybedal I; Haddock JA; Sansom DM; Lucena JM; Seidl M; Schmitt-Graeff A; Reiser V; Emmerich F; Frede N; Bulashevska A; Salzer U; Schubert D; Hayakawa S; Okada S; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Sumnik Z; Sediva A; Slatter M; Arkwright PD; Cant A; Lorenz HM; Giese T; Lougaris V; Plebani A; Price C; Sullivan KE; Moutschen M; Litzman J; Freiberger T; van de Veerdonk FL; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Speckmann C; Ehl S; Leichtner A; Blumberg R; Franke A; Snapper S; Zeissig S; Cunningham-Rundles C; Giulino-Roth L; Elemento O; Dückers G; Niehues T; Fronkova E; Kanderová V; Platt CD; Chou J; Chatila TA; Geha R; McDermott E; Bunn S; Kurzai M; Schulz A; Alsina L; Casals F; Deyà-Martinez A; Hambleton S; Kanegane H; Taskén K; Neth O; Grimbacher B
    J Allergy Clin Immunol; 2018 Dec; 142(6):1932-1946. PubMed ID: 29729943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DECTIN-1: A modifier protein in CTLA-4 haploinsufficiency.
    Turnbull C; Bones J; Stanley M; Medhavy A; Wang H; Lorenzo AMD; Cappello J; Shanmuganandam S; Pandey A; Seneviratne S; Brown GJ; Meng X; Fulcher D; Burgio G; Man SM; de Lucas Collantes C; Gasior M; López Granados E; Martin P; Jiang SH; Cook MC; Ellyard JI; Athanasopoulos V; Corry B; Canete PF; Vinuesa CG
    Sci Adv; 2023 Dec; 9(49):eadi9566. PubMed ID: 38055819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation.
    Alroqi FJ; Charbonnier LM; Baris S; Kiykim A; Chou J; Platt CD; Algassim A; Keles S; Al Saud BK; Alkuraya FS; Jordan M; Geha RS; Chatila TA
    J Allergy Clin Immunol; 2018 Mar; 141(3):1050-1059.e10. PubMed ID: 28601686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sporadic case of CTLA4 haploinsufficiency manifesting as Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Yuan H; Nishikori M; Ueda C; Fujimoto M; Yasumi T; Otsuka Y; Kitawaki T; Hirata M; Haga H; Kanegane H; Takaori-Kondo A
    J Clin Exp Hematop; 2022 Mar; 62(1):52-57. PubMed ID: 34707038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice.
    Serr I; Fürst RW; Achenbach P; Scherm MG; Gökmen F; Haupt F; Sedlmeier EM; Knopff A; Shultz L; Willis RA; Ziegler AG; Daniel C
    Nat Commun; 2016 Mar; 7():10991. PubMed ID: 26975663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
    Chen HH; Händel N; Ngeow J; Muller J; Hühn M; Yang HT; Heindl M; Berbers RM; Hegazy AN; Kionke J; Yehia L; Sack U; Bläser F; Rensing-Ehl A; Reifenberger J; Keith J; Travis S; Merkenschlager A; Kiess W; Wittekind C; Walker L; Ehl S; Aretz S; Dustin ML; Eng C; Powrie F; Uhlig HH
    J Allergy Clin Immunol; 2017 Feb; 139(2):607-620.e15. PubMed ID: 27477328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposing effects of CTLA4 insufficiency on regulatory versus conventional T cells in autoimmunity converge on effector memory in target tissue.
    Devarajan P; Miska J; Lui JB; Swieboda D; Chen Z
    J Immunol; 2014 Nov; 193(9):4368-80. PubMed ID: 25246499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTLA-4 expressed by FOXP3
    Klocke K; Holmdahl R; Wing K
    Immunology; 2017 Sep; 152(1):125-137. PubMed ID: 28497863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.